Why Is Follitropin Alfa (Gonal-F) So Hard to Find? [Explained for 2026]

If you've been handed a prescription for Gonal-F (follitropin alfa) and then spent hours on the phone with pharmacies only to hear "we don't carry that" or "we're out of stock," you're not alone. Follitropin alfa is one of the most challenging fertility medications to find in the United States in 2026 — and the reasons are more complicated than a simple supply hiccup.

In this guide, we'll break down exactly why follitropin alfa is so difficult to obtain, what's driving availability problems, and — most importantly — what you can do right now to find it.

What Is Follitropin Alfa (Gonal-F)?

Follitropin alfa is a recombinant (lab-made) form of follicle-stimulating hormone (FSH), a hormone your pituitary gland naturally produces to stimulate egg development. Sold under the brand name Gonal-F by EMD Serono, it was first FDA-approved in 1997 and has been a cornerstone of fertility treatment ever since.

It's used in three main situations: ovulation induction for women who have irregular or absent ovulation, controlled ovarian stimulation as part of IVF and other assisted reproductive technology (ART) cycles, and spermatogenesis induction in men with a condition called hypogonadotropic hypogonadism (low sperm counts caused by hormonal deficiency).

Is Follitropin Alfa (Gonal-F) in Shortage in 2026?

The short answer: Gonal-F is not always formally listed on the FDA Drug Shortage Database, but real-world availability has been consistently tight. Supply constraints have created a challenging landscape for patients and providers alike. Stock can vary significantly from week to week and from region to region — some specialty fertility pharmacies may have inventory while retail chain pharmacies have none at all.

The bottom line heading into 2026: plan ahead. Don't wait until the day you need to start injections to look for Gonal-F.

Why Is Follitropin Alfa So Hard to Find?

Several structural factors combine to make Gonal-F uniquely difficult to source:

1. It's a Complex Biologic — Not a Simple Pill

Follitropin alfa is produced using genetically modified Chinese Hamster Ovary (CHO) cells cultured in bioreactors. Unlike a small-molecule drug that can be synthesized in a lab relatively quickly, biologics like Gonal-F require living cell cultures, purification by immunochromatography, rigorous quality testing, and cold-chain logistics from factory to pharmacy. Each step takes time, and you can't simply "make more" on short notice when demand spikes.

2. There Is No Generic or Biosimilar Available in the US

As of 2026, there is no FDA-approved generic version or biosimilar of follitropin alfa in the United States. Biosimilar products like Ovaleap and Bemfola exist in Europe and are widely used there, but they have not received FDA approval. This means EMD Serono's Gonal-F is the only follitropin alfa option in the US market — with no competition and no backup if supply runs short.

3. Demand for Fertility Treatment Is Growing Fast

IVF and other assisted reproductive technologies are more accessible than ever before. Expanded insurance mandates in multiple states, growing cultural awareness, and the trend toward starting families later in life are all driving a steady increase in the number of patients pursuing fertility treatment. More patients means more demand for gonadotropins like Gonal-F — demand that the current supply chain is struggling to keep pace with.

4. Specialty Pharmacy Distribution Limits Access

Gonal-F requires cold-chain handling and is primarily distributed through specialty pharmacies rather than general retail chains. Your local CVS or Walgreens is unlikely to carry it. This creates a much smaller network of access points — and when those specialty pharmacies run low, patients have fewer places to turn.

5. Specific Strengths Are Harder to Find Than Others

Not all Gonal-F products are equally available. The 900 IU Redi-ject pen — the most popular format because it minimizes the number of injections needed — tends to go out of stock first. The 300 IU and 450 IU pens and the multi-dose vials (450 IU and 1050 IU) may still be available at pharmacies when the 900 IU pen is not. Your doctor can sometimes adjust your prescription format to accommodate what's in stock.

What Should I Do If I Can't Find Follitropin Alfa?

Here are concrete steps to take right now if you're struggling to find Gonal-F:

Contact specialty fertility pharmacies directly. Freedom Fertility, Encompass Rx, Alto Pharmacy, and Village Fertility Pharmacy often have stock when retail chains don't. Call several on the same day.

Call EMD Serono's Fertility Lifelines: 1-866-538-7879. They can sometimes help locate stock or connect you with suppliers.

Ask your fertility clinic. Many clinics have in-house dispensaries or preferred pharmacy partners with reserved stock for their patients.

Ask about switching pen strengths or vial formats. If the 900 IU pen is unavailable, your doctor may be able to rewrite your prescription for the 450 IU pen or multi-dose vials.

Discuss alternatives with your doctor. Follistim AQ (follitropin beta) is the most direct substitute and is functionally interchangeable for most protocols. Menopur is another option.

How medfinder Can Help

Instead of spending hours calling pharmacies yourself, medfinder does the calling for you. You provide your medication, dosage, and location — medfinder contacts pharmacies near you and lets you know which ones can fill your prescription. It's a straightforward way to cut through the frustration of pharmacy-hopping. You can also read our guide on how to find Gonal-F in stock near you for more strategies.

Will the Follitropin Alfa Supply Situation Improve?

Until an FDA-approved biosimilar enters the US market, the structural supply pressures for Gonal-F are unlikely to fully resolve. The good news is that a growing number of fertility clinics are establishing in-house dispensaries to ensure their patients can access critical medications. Additionally, expanding insurance coverage for fertility medications in more states is improving affordability, which may encourage investment in expanded manufacturing capacity over time.

For the latest on Gonal-F availability and shortage status, see our Gonal-F shortage update for 2026.